| Project/Area Number |
21J13093
|
|---|
| Research Category |
Grant-in-Aid for JSPS Fellows
|
| Allocation Type | Single-year Grants |
|---|
| Section | 国内 |
|---|
| Review Section |
Basic Section 35030:Organic functional materials-related
|
|---|
| Research Institution | Tohoku University |
|---|
Principal Investigator |
TAEMAITREE FARSAI 東北大学, 多元物質科学研究所, 特別研究員(PD)
|
|---|
| Project Period (FY) |
2021-04-28 – 2023-03-31
|
| Project Status |
Granted (Fiscal Year 2021)
|
| Budget Amount *help |
¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
Fiscal Year 2021: ¥1,040,000 (Direct Cost: ¥800,000、Indirect Cost: ¥240,000)
|
|---|
| Keywords | Drug delivery system / Nanoparticles / Dispersion stability / Surface modification |
|---|
| Outline of Research at the Start |
The aims of this research are to engineer the surface of carrier-free drug nanoparticles with cell membrane-derived vesicles and manipulate the dynamics of nanoparticles in complex environment. The newly established protocols are expected to advance the carrier-free drug nanoparticles to a multifunctional system with tunable targeting and drug release toward the personalized cancer therapeutic applications.
|
| Outline of Annual Research Achievements |
Surface modification strategies were carefully monitored to achieve drug nanoparticles with enhanced drug delivery efficiency (Chem. Lett. 2021, 50, 1555-1558; Mol. Crys. Liq. Crys., in press 2022). For the preparation of liposomal membrane modified drug nanoparticles, the coating on the drug nanoparticle surface was achieved by the sequential extrusion of membrane vesicle with the SN-38 drug nanoparticles model system. The modified drug nanoparticles were obtained in a slightly larger size, with narrow size distribution as confirmed by DLS. The liposomal layer on the nanoparticle’s surface was successfully confirmed by fluorescence and SEM images. In addition to the enhanced dispersion stability in the physiological environment, we have also shown that the liposomal membrane layer can be further modified to provide drug nanoparticles with specific cancer targeting and fluorescence imaging capability. The optimized protocol will be employed for the modification of drug nanoparticles with the liposomal membrane derived from natural sources such as red blood cells, white blood cells, and cancer cells.
|
| Current Status of Research Progress |
Current Status of Research Progress
1: Research has progressed more than it was originally planned.
Reason
翌年度、交付申請を辞退するため、記入しない。
|
| Strategy for Future Research Activity |
翌年度、交付申請を辞退するため、記入しない。
|
